Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BH3120 · 1 trial · 1 indication
To evaluate safety and tolerability of BH3120 as a single agent and in combination with pembrolizumab administration
To evaluate safety and tolerability of BH3120 as a single agent and in combination with pembrolizumab administration
| Arm | Type | Description |
|---|---|---|
| BH3120 | EXPERIMENTAL | Arm A: BH3120 Monotherapy |
| BH3120 + pembrolizumab | EXPERIMENTAL | Arm B: BH3120 in combination with pembrolizumab |
| Name | Type | Description |
|---|---|---|
| BH3120 | DRUG | BH3120 will be administered as an IV infusion over 90 minutes on Day 1 of every 3-week treatment cycle |
| pembrolizumab | DRUG | Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle |
Key Inclusion Criteria: * Have a Histologically or cytologically confirmed non-CNS solid tumor that is metastatic or unresectable and for whom there is no available standard therapy. * PD-L1 positive expression (Tumor Proportion Score ≥1% or Combined Positive Score ≥1). * Have at least one lesion, ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
BH3120 is an investigational small molecule being developed for the treatment of advanced or metastatic solid tumors. It is currently being studied in a Phase 1 clinical trial that includes patients with these types of cancer. The drug is administered either alone or in combination with pembrolizumab, another cancer therapy.
BH3120 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of BH3120 in patients with advanced or metastatic solid tumors.
BH3120 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is a dose escalation and expansion study that is actively recruiting participants with advanced or metastatic solid tumors.
BH3120 is being studied in a single Phase 1 clinical trial registered as NCT06234397. This trial is titled 'Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors' and is currently recruiting participants in the United States and South Korea.
Yes, BH3120 is being evaluated both as a monotherapy and in combination with pembrolizumab in a Phase 1 clinical trial. The trial is designed to assess the safety and tolerability of BH3120 when given alone or with pembrolizumab in patients with advanced or metastatic solid tumors.
The Phase 1 clinical trial for BH3120, identified as NCT06234397, has a planned enrollment of 245 participants. The study is currently recruiting patients aged 18 years and older with advanced or metastatic solid tumors, and it is being conducted at sites in the United States and South Korea.